TG THERAPEUTICS INC

New TG Therapeutics Phase 1 data shows sub‑cutaneous ublituximab (BRIUMVI) is safe, well‑tolerated, and delivers comparable exposure to IV, hinting at a future quarterly dosing and market expansion.

Discover how TG Therapeutics is advancing breakthrough treatments for relapsed and refractory non‑Hodgkin’s lymphoma, positioning itself as a leading oncology innovator with a $5.28 billion market cap.

TG Therapeutics Inc, a clinical-stage biopharmaceutical company, is a high-stakes investment opportunity with promising therapies for cancer treatment, but its high valuation and market volatility raise concerns about its future prospects.

TG Therapeutics, a clinical-stage biopharmaceutical company, is advancing in cancer treatment with a focus on hematological malignancies and innovative pharmaceutical products.

TG Therapeutics Inc is a high-risk, high-reward biotech company with a market cap of $5.44 billion, navigating financial, strategic, and market challenges as it pursues innovative treatments for hematological malignancies.

TG Therapeutics Inc. has reported strong sales growth and raised its revenue outlook, driven by the success of its flagship therapy BRIUMVI, despite facing market challenges and competition in the biotech sector.

TG Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing innovative cancer treatments, with a focus on hematological malignancies and a market capitalization of approximately $6.33 billion.